Rapamycin Treatment Reduces Brain Pericyte Constriction in Ischemic Stroke

Daniel J Beard1,2, Lachlan S Brown3, Gary P Morris3

  • 1Acute Stroke Programme, Radcliffe Department of Medicine, University of Oxford, Oxford, UK. daniel.j.beard@newcastle.edu.au.

PubMed

Insights

Rapamycin, a target of rapamycin (mTOR) inhibitor, reduces brain pericyte contraction during stroke. This improves capillary blood flow after artery reopening, suggesting its therapeutic potential for stroke recovery.

Area of Science:

  • Neuroscience
  • Vascular Biology
  • Pharmacology

Background:

  • Brain pericyte contraction and death contribute to microvascular no-reflow after ischemic stroke.
  • Mammalian target of rapamycin (mTOR) inhibition reduces cancer cell motility and neuronal death in stroke.
  • The effect of mTOR inhibition on brain pericytes during ischemia is unknown.

Purpose of the Study:

  • To investigate the impact of mTOR inhibition on brain pericyte contraction and viability during ischemia.
  • To evaluate the therapeutic potential of rapamycin in a mouse model of ischemic stroke.

Main Methods:

  • In vitro study of cultured pericytes under simulated ischemia.
  • Assessment of pericyte contraction and viability with and without rapamycin.
  • In vivo study using a mouse model of middle cerebral artery occlusion and recanalization.

Main Results:

  • Pericytes contracted within 1 hour and died after 7 hours of simulated ischemia.
  • Rapamycin significantly reduced pericyte contraction rate but did not affect viability.
  • Rapamycin increased capillary diameter and the number of open capillaries post-stroke in mice.

Conclusions:

  • mTOR inhibition by rapamycin mitigates pericyte contraction during ischemia via a calcium-independent pathway.
  • Rapamycin enhances cerebral reperfusion by improving capillary patency after stroke.
  • Rapamycin shows promise as an adjuvant therapy to improve outcomes post-ischemic stroke.